Short-term treatment with the antidepressant fluoxetine triggers pyramidal dendritic spine synapse formation in rat hippocampus.

Department of Obstetrics, Gynaecology and Reproductive Sciences, Yale University School of Medicine, 333 Cedar Street, FMB 312, New Haven, CT 06520-8063, USA.
European Journal of Neuroscience (Impact Factor: 3.67). 04/2005; 21(5):1299-303. DOI: 10.1111/j.1460-9568.2005.03968.x
Source: PubMed

ABSTRACT The pathomechanism of major depressive disorder and the neurobiological basis of antidepressant therapy are still largely unknown. It has been proposed that disturbed hippocampal activity could underlie some of the cognitive and vegetative symptoms of depression, at least in part because of loss of pyramidal cell synaptic contacts, a process that is likely to be reversed by antidepressant treatment. Here we provide evidence that daily administration of the antidepressant fluoxetine to ovariectomized female rats for 5 days induces a robust increase in pyramidal cell dendritic spine synapse density in the hippocampal CA1 field, with similar changes appearing in CA3 after 2 weeks of treatment. This rapid synaptic remodelling might represent an early step in the fluoxetine-induced cascade of responses that spread across the entire hippocampal circuitry, leading to the restoration of normal function in the hippocampus. Hippocampal synaptic remodelling might provide a potential mechanism to explain certain aspects of antidepressant therapy and mood disorders, especially those associated with changes in reproductive state in women, that cannot be reconciled adequately with current theories for depression.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Major depressive disorder is the most common psychiatric disorder in the world, affecting 350 million people worldwide. According to the World Health Organization (WHO), it is expected to become the second greatest cause of illness by 2020. For individuals in the age group of 15–44 years, major depression is already considered as the first cause of disease in the 2012 WHO survey. Thus, as the social burden continues to increase worldwide, the need to study the causes and treatment of major depression has been rapidly growing. Due to the limited efficacy of chemical-based antidepressants, which have been used for the treatment of major depression, new antidepressants and gene targeting therapies are garnering more attention in treatment of major depressive disorder. To identify the genes responsible for major depressive disorder, many gene-profiling studies have been performed on various regions of postmortem human brains with major depression and compared to control brains. In this review, it is examined gene expression changes in the prefrontal cortex of patients with major depression compared to that in the normal population using high throughput analysis and bioinformatics. It is also discussed how this altered gene expression can contribute to structural and functional losses in the brain of patients with major depression. In the concluding part, it is considered the possibility that GATA1 – a newly identified transcriptional repressor for synapse-related genes under stressed condition, which induced depressive behavior by high copy expression in the dorsolateral prefrontal cortex of rodents – can be developed as a new therapeutic target for major depressive disorder.
    Animal cells and systems the official publication of the Zoological Society of Korea 09/2014; 18(5). DOI:10.1080/19768354.2014.968204 · 0.35 Impact Factor
  • Source
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Depression is a devastating psychiatric disorder widely attributed to deficient monoaminergic signaling in the central nervous system. However, most clinical antidepressants enhance monoaminergic neurotransmission with little delay but require 4-8 weeks to reach therapeutic efficacy, a paradox suggesting that the monoaminergic hypothesis of depression is an oversimplification. In contrast to the antidepressants targeting the monoaminergic system, a single dose of the N-methyl-D-aspartate receptor (NMDAR) antagonist ketamine produces rapid (within 2 h) and sustained (over 7 days) antidepressant efficacy in treatment-resistant patients. Glutamatergic transmission mediated by NMDARs is critical for experience-dependent synaptic plasticity and learning, processes that can be modified indirectly by the monoaminergic system. To better understand the mechanisms of action of the new antidepressants like ketamine, we review and compare the monoaminergic and glutamatergic antidepressants, with emphasis on neural plasticity. The pathogenesis of depression may involve maladaptive neural plasticity in glutamatergic circuits that may serve as a new class of targets to produce rapid antidepressant effects.
    Neuroscience Bulletin 02/2015; 31(1):75-86. DOI:10.1007/s12264-014-1484-6 · 1.83 Impact Factor